A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of SEP-631 in Healthy Adult Volunteers
Latest Information Update: 24 Jul 2025
At a glance
- Drugs SEP 631 (Primary)
- Indications Chronic urticaria; Mastocytosis
- Focus Adverse reactions
- Sponsors Septerna
Most Recent Events
- 15 May 2025 According to a Septerna media release, company expects to Initiate Phase 1 Trial for SEP-631, in third quarter of 2025.
- 27 Mar 2025 According to a Septerna media release, company anticipates initiating a Phase 1 clinical trial in 2025
- 04 Dec 2024 New trial record